Ideaya Biosciences (IDYA) PT Raised to $31 at Roth Capital
- Nasdaq ends at record high as Big Tech roars back
- Sanderson Farms (SAFM) Explores Sale - Report
- Bitcoin (BTC) Cracks $30,000 to Hit 6-Month Low, Here Are Next Targets Lower
- Dollar lower as Powell reaffirms pledge to not raise rates too quickly
- Splunk (SPLK) Lands $1 Billion From Silver Lake, Announces Buyback One Day After Activist Rumors Surface
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Roth Capital analyst Zegbeh Jallah raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $31.00 (from $23.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Credit Suisse Upgrades Kinross Gold (KGC) to Outperform
- ASMedia Technology inc. (5269:TT) PT Raised to NT$1,750 at CLSA
- Salvatore Ferragamo SpA (SFER:IM) (SFRGY) PT Raised to EUR19.50 at UBS
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesRoth Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!